At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 139 enrolled
Drug / intervention
Midodrine +1 moredrug
Likely dose
Midodrine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Midodrine for the Treatment of Refractory Hypotension in Patients Otherwise Ready for Discharge From the ICU
In Brief
A Phase 3 clinical trial evaluating Midodrine and Placebo for Hypotension and Critical Illness. Completed, enrolled 139 participants across 3 sites in 2 countries.
Detailed Summary
We hypothesize that midodrine treatment of refractory hypotension in patients otherwise ready for discharge from the ICU shortens duration of receiving IV vasopressors and SICU length of stay without increasing MGH length of stay or putting the patient at risk of being readmitted to an ICU.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypotension, Critical Illness
CountriesAustralia, United States
CollaboratorsSir Charles Gairdner Hospital
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2012
Enrollment StartApr 2012
Primary CompletionJun 2019
TodayJul 2026
First PostedFeb 13, 2012
Enrollment StartApr 1, 2012
Primary CompletionJun 1, 2019
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 14.4 years ago
Interventions
Midodrinedrug
Patients will be randomized to blinded to 20 mg of midodrine
Placebodrug
Patients will be randomized to blinded placebo control